Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Meiragtx Holdings ( (MGTX) ) just unveiled an announcement.
On December 31, 2025, MeiraGTx Holdings plc agreed to repurchase 2.3 million of its ordinary shares from Perceptive Life Sciences Master Fund, an affiliate of Perceptive Advisors, at $7.91 per share, matching the Nasdaq volume-weighted average price that day, for a total of approximately $18.2 million; Perceptive Master Fund sold the shares as part of year-end portfolio tax optimization. As part of the agreement, Perceptive Master Fund and its affiliates, which collectively own more than 10% of MeiraGTx’s outstanding shares and whose affiliate Perceptive Credit Holdings III also holds a $75 million company note, consented to the repurchase and accepted a 12‑month lock-up on further share sales, a move that reinforces a stable shareholder base and underscores the tight financial and governance links between MeiraGTx and its key biotech-focused investor, whose executive Ellen Hukkelhoven also serves on the company’s board.
The most recent analyst rating on (MGTX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Meiragtx Holdings stock, see the MGTX Stock Forecast page.
Spark’s Take on MGTX Stock
According to Spark, TipRanks’ AI Analyst, MGTX is a Neutral.
Meiragtx Holdings’ overall stock score is primarily impacted by its financial challenges, including declining revenues and high leverage. However, the strategic collaboration with Eli Lilly provides a significant positive outlook, potentially enhancing future revenue streams. Technical indicators suggest moderate strength, while valuation remains a concern due to negative profitability.
To see Spark’s full report on MGTX stock, click here.
More about Meiragtx Holdings
MeiraGTx Holdings plc is a biotechnology company focused on developing gene therapy treatments, with its ordinary shares listed on the Nasdaq Global Select Market and a shareholder base that includes specialized life sciences investors such as Perceptive Advisors’ affiliated funds.
Average Trading Volume: 533,991
Technical Sentiment Signal: Buy
Current Market Cap: $639.9M
See more insights into MGTX stock on TipRanks’ Stock Analysis page.